Investor Relations

Eos SENOLYTIX is a longevity company using MitoXcel™ Technology to develop novel therapeutics targeting the fundamental mechanisms of aging. Its lead clinical candidates, PTC-2105 and PTC-2107, both proprietary MitoXcel™ geropeptides, have demonstrated the ability to rejuvenate naturally aged mice via two separate mechanisms, both targeting the mitochondrial membrane potential (MMP), also called the “Δψm” (pronounced “delta psi em”), the difference in electrical potential between the mitochondrial matrix and the cytosol generated as protons are pumped out during the process of oxidative phosphorylation, during which the mitochondria “burn” carbohydrates, fats, and proteins, turning them into into ATP molecules, the packets of energy used by cells to fuel all of life’s processes, in the presence of oxygen.

The company’s MitoXcel™ geropeptides work via a novel mechanism of action; they target the lower and declining MMP (“Δψm”) found in all cells, including senescent cells which develops as we age, that reduces mitochondrial function and ATP production, a universal finding across all living species as they age. By targeting this single, aging-specific target, these geropeptides have demonstrated the ability to rejuvenate naturally aged mice via two separate mechanisms: (1) to return the efficiency of mitochondrial function in aging cells almost immediately back to their younger, more efficient phenotype, and (2) to steadily and profoundly eliminate senescent cells throughout every organ in the body, including the brain, reducing their negative systemic inflammatory effects, with no apparent adverse side effects observed. By targeting the fundamental processes driving aging and aging-related diseases, Eos SENOLYTIX may have discovered a unique therapeutic opportunity to intervene in the aging process in ways that were once thought impossible, to improve healthspan and increase lifespan.